Anatomic and phylogenetic distribution of somatostatin

Vale, Wylie; Ling, N; Rivier, Jean; Villarreal, Jose; Rivier, Catherine; Douglas, Carolyn J.; Brown, Marvin

doi:10.1016/s0026-0495(76)80175-8

Cited by 160 publications

(44 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IRS was assayed in every sample by a double-antibody modification of the method of Arimura et al (13,14) using rabbit antiserum #101. The standard dilution curve was set up with perfusate as a diluent.…”

Section: Methodsmentioning

confidence: 99%

Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.

Ipp¹,

Dobbs²,

Arimura³

et al. 1977

J. Clin. Invest.

168

View full text Add to dashboard Cite

A B S T R A C T The effects of glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide upon the release of immunoreactive somatostatin (IRS) from the isolated perfused pancreas were studied. In seven experiments in which glucose was perfused either at a concentration of 100 or 350 mg/dl or at 25 mg/dl, IRS levels were significantly greater at-the higher glucose concentrations. In three doseresponse experiments in which the perfusing glucose concentration was increased at 30-min intervals from an initial concentration of 25 mg/dl to a final concentration of 300 mg/dl, progressive increases in IRS release were noted at glucose concentrations of 100 mg/dl and above. Perfusion of a 20 mM mixture of 10 amino acids also elicited a prompt and significant biphasic IRS rise in each of six experiments. In five experiments, 20 mM leucine evoked a similar response in mean IRS. Perfusion with 0.075 Ivy U/ml of pancreozymin-cholecystokinin, with or without the presence of a 1 mM 10-amino acid mixture, elicited a prompt rise in IRS with a pattern resembling that of insulin in a total of six experiments. Tolbutamide (0.75 mg/min) also stimulated IRS release in five of six challenges. The IRS responses to nutrients and to pancreozymin and their similarity to the insulin responses raise the possibility that, like insulin, pancreatic somatostatin may have an endocrine role related to nutrient homeostasis.

show abstract

Section: Methodsmentioning

confidence: 99%

Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide.

Ipp¹,

Dobbs²,

Arimura³

et al. 1977

J. Clin. Invest.

168

View full text Add to dashboard Cite

show abstract

“…It was known early, however, that the SRIF in the nervous system occurs not only in endothermic vertebrates but also in amphibians and bony fish (DUBOIS et al, 1974). As to the presence of SRIF-storing cells in the GEP endocrine system of ectothermic animals, there are only a few recent reports, giving the actual tissue contents by radioimmunoassays and the immunocytochemical localization of SRIF-cells in bony fishes and cyclostomes (VALE et al, 1976;JOHNSON et al, 1976; VAN NOORDEN et al, 1977;see also FALKMER and OsTBERG,1977). In addition, there are some biosynthetic studies on SRIF, using the islet parenchyma of a bony fish (NoE et al, 1977).…”

Section: Jan-bertil Siljevall6mentioning

confidence: 99%

Some Phylogenetical Aspects on the Occurrence of Somatostatin in the Gastro-Entero-Pancreatic Endocrine System

Falkmer

Elde

Hellerström

et al. 1977

Arch. Histol. Jap., Arch. Histol. Jpn

View full text Add to dashboard Cite

“…Somatostatin-like immunoreactivity and bioactivity are widely distributed in the central nervous system and in the digestive tract tissues [4-71. Size heterogeneity described in somatostatin-like immunoreactive materials [3,6,8,9] raised the possibility of the existence of prohormonal forms of this molecule [lO,l 11. During the purification of porcine intestinal somatostatin differences were noticed in the chromatographic behaviour of immunoreactive fractions and synthetic somatogtatin- 14 [ 121. A novel intestinal peptide was then isolated and partly characterized as an N-terminally extended form of somatostatin [ 131. We report here the primary structure of this intestinal peptide which has been found to be an octacosapeptide, somatostatin-28.…”

Section: Introductionmentioning

confidence: 99%